Related Experiment Video
Updated: Jul 16, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status
Jalayne Arias1, Drew Blasco2, Anya E R Prince3
1Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta.
Neurology
|July 14, 2026
Summary
Neurodegenerative biomarker information raises discrimination risks. This study proposes an evidence-based policy strategy to update legal protections, ensuring patient interests are prioritized.
Area of Science:
- Neuroscience
- Biomarkers
- Genetics
Background:
- Neurodegenerative biomarkers detect disease pathology pre-clinically.
- Expanding biomarker use raises legal and privacy concerns.
- Early-stage individuals face potential discrimination in employment, insurance, and housing.
Purpose of the Study:
- Evaluate current legal protections for neurodegenerative biomarker information.
- Propose a policy agenda to address discrimination risks.
- Ensure patient interests align with biomarker testing advancements.
Main Methods:
- Comprehensive evaluation of existing legal protections.
- Development of empirical evidence to inform policy priorities.
- Iterative approach to policy development and strategy.
Main Results:
- Existing privacy and antidiscrimination laws have potential gaps.
- Novel legal questions arise with clinical biomarker adoption.
- Need for evidence-based policy to address discrimination risks.
Conclusions:
- An evidence-informed, iterative policy strategy is crucial.
- Recommendations focus on building existing legal mechanisms and identifying gaps.
- Prioritizing future policy goals requires understanding legislative aims and unintended consequences.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
00:49The Blood-brain Barrier
Overview
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...